Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric tolvaptan study in autosomal dominant polycystic kidney disease
2016-000187-42Phase 3Unknown
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tolvaptan in autosomal dominant polycystic kidney disease (ADPKD) (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Change from baseline in spot urine osmolality and Change from baseline in urine specific gravity. Status: unknown.
02
Drugs
tolvaptan
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2016-000187-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000187-42.